CD226: A Promising Drug Target and Biomarker for Chronic Pain

CD226: A Promising Drug Target and Biomarker for Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The persistent nature of pain, often associated with various underlying conditions, can significantly impact an individual's quality of life and overall prognosis. As such, the development of new treatments for chronic pain remains a major focus of research. CD226, a protein that is expressed in various tissues and cell types, has emerged as a promising drug target and biomarker for chronic pain.

CD226: Structure and Function

CD226 is a cell adhesion molecule that is expressed in various tissues, including the brain, pancreas, and gastrointestinal tract. Its primary function is to mediate cell-cell adhesion, which is critical for tissue repair and regeneration. CD226 is a 226-kDa protein that consists of an N-terminus, a transmembrane region, and a C-terminus. The N-terminus of CD226 contains a nucleotide-binding oligomerization domain (NBD), which is known to play a role in protein-protein interactions.

CD226 has been shown to participate in various signaling pathways, including the TGF-β and Wnt signaling pathways. TGF-β is a well-established mediator of pain modulation, and CD226 has been shown to regulate TGF-β signaling in various cell types. Wnt signaling, on the other hand, is involved in the development of pain modulation in the brain and is implicated in the pathophysiology of chronic pain.

CD226 as a Drug Target

The potential of CD226 as a drug target for chronic pain comes from its involvement in multiple signaling pathways. The NBD domain of CD226 has been shown to interact with various proteins, including TGF-β, Smad, and 尾-catenin. This interaction suggests that CD226 could be a useful target for drugs that can modulate these signaling pathways.

One class of drugs that have been shown to interact with CD226 is small molecules. For instance, a commonly used drug for the treatment of chronic pain, nonsteroidal anti-inflammatory drugs (NSAIDs), have been shown to inhibit the activity of CD226. This is because CD226 is involved in the regulation of pain signaling, and inhibiting its activity can lead to the termination of pain signaling pathways. Therefore, drugs that can modulate CD226 activity could be effective in treating chronic pain.

Another class of drugs that may be effective in treating chronic pain by modulating CD226 activity are monoclonal antibodies (MCAs). MCAs are laboratory-produced antibodies that can be used to target specific proteins with high affinity. CD226 is a protein that has been identified as a potential target for MCAs, and several studies have shown that these antibodies can effectively reduce pain in animal models of chronic pain. Therefore, MCAs may be an attractive tool for the development of new treatments for chronic pain.

CD226 as a Biomarker

In addition to its potential as a drug target, CD226 has also been shown to be a promising biomarker for chronic pain. The levels of CD226 in various tissues, including pain-related tissues, have been shown to be affected by pain exposure and may be used as an indicator of pain severity.

CD226 has been shown to be involved in the regulation of pain signaling in various tissues. For instance, studies have shown that CD226 is involved in the regulation of pain signaling in the brain, and its activity has been shown to be modulated by various pain-related stimuli. Therefore, the levels of CD226 in the brain may be an indicator of the severity and location of pain.

CD226 has also been shown to be involved in the regulation of pain signaling in peripheral tissues, including pain-related muscles and tissues. Therefore, the levels

Protein Name: CD226 Molecule

Functions: Involved in intercellular adhesion, lymphocyte signaling, cytotoxicity and lymphokine secretion mediated by cytotoxic T-lymphocyte (CTL) and NK cell (PubMed:8673704). Cell surface receptor for NECTIN2. Upon ligand binding, stimulates T-cell proliferation and cytokine production, including that of IL2, IL5, IL10, IL13, and IFNG. Competes with PVRIG for NECTIN2-binding (PubMed:26755705)

The "CD226 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD226 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB